Teva Issues Statement

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. META
5. MU
6. NVDA
7. BLZE
8. IBM
9. PRIM
10. ACN

Go back to Teva Issues Statement

Teva Pharma (TEVA) to Acquire Allergan Genetics (AGN) in $40.5B Cash and Stock Deal

July 27, 2015 6:03 AM EDT

Teva Pharma (NYSE: TEVA) announced that it has signed a definitive agreement with Allergan plc (NYSE: AGN) to acquire Allergan Generics in a transaction valued at $40.5 billion. Upon closing, Allergan will receive $33.75 billion in cash and shares of Teva valued today at $6.75 billion, representing an estimated under 10% ownership stake in Teva, with the number of Teva shares determined based on Tevas volume weighted average trading prices during the 15 days prior to the announcement and five days following the announcement. Teva believes the acquisition will be significantly accretive to... More

Teva Pharma (TEVA) Comments on Stichting's Move to Exercise Call Option on Mylan (MYL); Sees as 'Unwarranted'

July 23, 2015 9:06 AM EDT

Teva Pharma (NYSE: TEVA) issued the following statement regarding Stichting Preferred Shares Mylans (Nasdaq: MYL) decision to exercise its call option:

We strongly disagree with the stated analysis of Stichting Preferred Shares Mylan and its decision... More